Results 11 to 20 of about 2,828,087 (336)

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.

New England Journal of Medicine, 2023
BACKGROUND Isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death.
I. Mellinghoff, M. J. van den Bent, D. Blumenthal, M. Touat, K. Peters, Jennifer L. Clarke, Joe S. Mendez, S. Yust-Katz, L. Welsh, W. Mason, F. Ducray, Y. Umemura, B. Nabors, M. Holdhoff, A. Hottinger, Yoshiki Arakawa, J. Sepúlveda, W. Wick, R. Soffietti, J. Perry, P. Giglio, M. I. de la Fuente, E. Maher, S. Schoenfeld, Dan Zhao, S. Pandya, L. Steelman, Islam Hassan, P. Wen, T. Cloughesy   +29 more
semanticscholar   +1 more source

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

New England Journal of Medicine, 2021
BACKGROUND Human epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small-cell lung cancer (NSCLC).
Bob T. Li, E. Smit, Y. Goto, K. Nakagawa, H. Udagawa, J. Mazières, M. Nagasaka, L. Bazhenova, A. Saltos, E. Felip, J. Pacheco, M. Pérol, L. Paz-Ares, K. Saxena, R. Shiga, Yingkai Cheng, S. Acharyya, P. Vitazka, J. Shahidi, D. Planchard, P. Jänne   +20 more
semanticscholar   +1 more source

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Blood, 2022
Substantial heterogeneity within mutant TP53 acute myeloid leukemia (AML) and myelodysplastic syndrome with excess of blast (MDS-EB) precludes the exact assessment of prognostic impact for individual patients. We performed in-depth clinical and molecular
T. Grob, A. A. Al Hinai, M. Sanders, F. Kavelaars, M. Rijken, P. Gradowska, B. Biemond, D. Breems, J. Maertens, M. van Marwijk Kooy, T. Pabst, O. de Weerdt, G. Ossenkoppele, A. A. van de Loosdrecht, G. Huls, J. Cornelissen, H. Beverloo, B. Löwenberg, M. Jongen‐Lavrencic, P. Valk   +19 more
semanticscholar   +1 more source

Targeting mutant p53 for cancer therapy: direct and indirect strategies

Journal of Hematology & Oncology, 2021
TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 protein oncogenic properties.
Jiahao Hu, Jiasheng Cao, Win Topatana, Sarun Juengpanich, Shijie Li, Bin Zhang, Jiliang Shen, Liu-xin Cai, Xiujun Cai, Mingyu Chen   +9 more
semanticscholar   +1 more source

Somatic mutant clones colonize the human esophagus with age

Science, 2018
The mutational burden of aging As people age, they accumulate somatic mutations in healthy cells. About 25% of cells in normal, sun-exposed skin harbor cancer driver mutations.
I. Martincorena, J. Fowler, Agnieszka Wabik, A. Lawson, F. Abascal, M. Hall, A. Cagan, K. Murai, Krishnaa T. Mahbubani, M. Stratton, R. Fitzgerald, P. Handford, P. Campbell, K. Saeb‐Parsy, P. Jones   +14 more
semanticscholar   +1 more source

Genetic compensation triggered by mutant mRNA degradation

Nature, 2019
Genetic robustness, or the ability of an organism to maintain fitness in the presence of harmful mutations, can be achieved via protein feedback loops. Previous work has suggested that organisms may also respond to mutations by transcriptional adaptation,
Mohamed A. El-Brolosy, Zacharias Kontarakis, Andrea Rossi, C. Kuenne, S. Günther, Nana Fukuda, Khrievono Kikhi, Giulia L. M. Boezio, Carter M. Takacs, S. Lai, R. Fukuda, C. Gerri, Antonio J. Giráldez, D. Stainier   +13 more
semanticscholar   +1 more source

Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials [PDF]

, 2006
Recent studies suggest that the toxicity of familial amyotrophic lateral sclerosis mutant Cu, Zn superoxide dismutase (SOD1) arises from its selective recruitment to mitochondria. Here we demonstrate that each of 12 different familial ALS-mutant SOD1s
Butler Gralla, Edith, Carrì, Maria Teresa, Casciati, Arianna, Cozzolino, Mauro, Crosio, Claudia, Ferri, Alberto, Nencini, Monica, Rotilio, Giuseppe, Valentine, Joan Selverstone   +8 more
core   +2 more sources

Phenotypic mixing and hiding may contribute to memory in viral quasispecies [PDF]

, 2003
Background. In a number of recent experiments with food-and-mouth disease virus, a deleterious mutant, was found to avoid extinction and remain in the population for long periods of time. This observation was called quasispecies memory.
Novella, Isabel S., Wilke, Claus O.
core   +4 more sources

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Nature, 2018
Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically ...
David M. Hyman, S. Piha-Paul, H. Won, J. Rodón, C. Saura, Geoffrey I. Shapiro, D. Juric, David I. Quinn, V. Moreno, B. Doger, I. Mayer, V. Boni, E. Calvo, S. Loi, A. C. Lockhart, J. Erinjeri, M. Scaltriti, G. Ulaner, J. Patel, Jiabin Tang, H. Beer, S. D. Selcuklu, Aphrothiti J. Hanrahan, N. Bouvier, Myra Melcer, R. Murali, A. Schram, L. Smyth, K. Jhaveri, Bob T. Li, A. Drilon, J. Harding, G. Iyer, Barry S. Taylor, Michael F. Berger, R. Cutler, Feng Xu, A. Butturini, L. Eli, G. Mann, C. Farrell, A. Lalani, R. Bryce, Carlos L. Arteaga, F. Meric-Bernstam, J. Baselga, D. Solit   +46 more
semanticscholar   +1 more source

The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic

Nature, 2020
Somatic mutations in p53, which inactivate the tumour-suppressor function of p53 and often confer oncogenic gain-of-function properties, are very common in cancer 1 , 2 .
E. Kadosh, Irit Snir-Alkalay, Avanthika Venkatachalam, Shahaf May, Audrey Lasry, Ela Elyada, A. Zinger, Maya Shaham, Gitit Vaalani, M. Mernberger, T. Stiewe, E. Pikarsky, M. Oren, Y. Ben-Neriah   +13 more
semanticscholar   +1 more source